bringing energy to life
Khondrion is a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease.
Khondrion is a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease. Based on proprietary science and a deep understanding of mitochondrial dysfunction, the company is advancing its wholly owned lead drug candidate sonlicromanol for the treatment of both children and adults.
working with others
At Khondrion we know that working in collaboration with others is important to accelerate the development of innovative new medicines. That is why we are pursuing cutting edge science both within our own labs and through partnerships across an extensive academic and industry network of experts and are sharing knowledge around mitochondrial disease in close collaboration with patient organizations to help develop important new medicines and treatments for patients.
“the solution is within our reach”
Since 2012 Khondrion has been progressing a pipeline with the potential to deliver transformative medicines for patients living with mitochondrial disease.
get in touch
Whether you are a researcher, job seeker, health professional, patient, potential investor or potential business partner, you can contact us using this form.